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Abstract Various inhibitors were tested for their potential to 
suppress the kinase activity of protein kinase C tt (PKC~t) in 
vitro and in vivo. Among the staurosporine-derived, rather 
selective PKC inhibitors the indolocarbazole G6 6976 previously 
shown to inhibit preferentially cPKC isotypes proved to be a 
potent inhibitor of PKC~t with an IC5o of 20 nM, whereas the 
bisindolylmaleimide G6 6983 was extremely ineffective in 
suppressing PKCtt kinase activity with a thousand-fold higher 
ICso of 20 ~M. Other strong inhibitors of PKC~t were the rather 
unspecific inldbitors staurosporine and K252a. Contrary to the 
poor inhibition of PKCtt by G~ 6983, this compound was found 
to suppress in vitro kinase activity of PKC isoenzymes from all 
three subgroups very effectively with IC5o values from 7 to 60 
nM. Thus, Gii 6983 was able to differentiate between PKC~t and 
other PKC isoenzymes being useful for selective determination of 
PKC~t kinase activity in the presence of other PKC isoenzymes. 
l~ey words: Protein kinase Cp.; Protein kinase C isoenzyme; 
Protein kinase C inhibitor; Staurosporine; 
A utophosphorylation 
1. Introduction 
Protein kinase C (PKC) is a family of phospholipid-depend- 
e~t serine/threonine protein kinases that plays a central role in 
signal transduction and is involved in the control of numerous 
cellular processes, uch as proliferation and differentiation, as 
well as in carcinogenesis (for reviews see [14]). Members of 
the PKC family have been grouped into three categories. The 
cPKCs (c~, 131,132, y) are calcium-dependent and activated by 
diacylglycerol or phorbol ester. The nPKCs (~5, e, q, 0) are 
calcium-unresponsive and, as cPKCs, activated by diacylgly- 
cerol or phorbot ester whereas the aPKCs (~,t/~) are unre- 
sponsive to both calcium and diacylglycerol r phorbol ester. 
Recently the cDNA of a novel serine/threonine protein ki- 
nase was isolated from a human placenta cDNA library. Re- 
ferring to its structural similarities to the PKC family, such as 
the: combination of amino terminal cysteine clusters a carboxy 
telminal kinase domain, and its phospholipid ependency, the 
kiaase was termed PKC/x [5]. Upon overexpression in various 
cell lines and immunoprecipitation, the novel PKC isoenzyme 
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could be partially characterized and was found to be calcium- 
independent but phorbol ester responsive [6]. Due to these 
properties PKCIa might have been classified as a member of 
the nPKC subgroup of the PKC family. However, PKC~t sig- 
nificantly differs in some structural features from the other 
PKC isotypes known so far [5]. With a sequence of 912 amino 
acids PKC~t is larger than the other PKCs. It contains a 
hydrophobic domain in the N-terminal region and a pleck- 
strin homology (PH) domain [7] which is currently discussed 
as a potential region for protein/protein teractions or lipid 
binding [8,9]. PKC/a does not contain a region homologous to 
pseudosubstrate regions of other PKC family members. How- 
ever, this does not exclude the possibility of a quite different 
pseudosubstrate motif to exist. Very recently, a protein kinase, 
named PKD, was discovered [10] which most likely is the 
murine homolog of human PKC~t. It was reported that 
PKD failed to phosphorylate s veral substrates which are ac- 
tively phosphorylated by other members of the PKC family. 
The only substrate for PKCp./PKD known so far are the 
synthetic peptides yntide 2 and GS [10,11] According to its 
structural and functional properties, PKCpJPKD appears to 
be a member of the PKC family but cannot be included in any 
of the three subgroups. Several reports have indeed indicated 
the involvement of PKC isoenzymes in specific cellular pro- 
cesses, like differentiation (PKC~i) and proliferation (PKCe) of 
specific cells (for a review see [3]). To address uch questions 
the identification of PKC subtype specific inhibitors will be 
valuable tools for respective investigations. 
Here we report on the suppression of PKC~t activity by 
various inhibitors and show how PKC/a activity can be differ- 
entiated from the activity of other known PKC isotypes by 
means of one of these inhibitors. This selective inhibitor 
promises to become an important ool for the investigation 
of specific in vivo functions of PKC~t. Moreover, our data 
support the above-mentioned xceptional position of PKC~t 
and the idea to classify it as a member of a novel subgroup of 
the PKC family. 
2. Materials and methods 
2.1. Materials 
12-O-Tetradecanoylphorbol 13-acetate (TPA) and bryostatin 1were 
supplied by Prof. E. Hecker (German Cancer Research Center, Hei- 
delberg, Germany) and Prof. G.R. Pettit (State University of Arizona, 
Tempe, AZ, USA), respectively. G6 6976 and G6 6983 were kindly 
provided by Goedecke A.G. (Freiburg, Germany). Syntide 2, the 
pseudosubstrate of PKCS, the pseudosubstrate-related peptide of 
PKCS, and peptides 1-3 were synthesized by Dr. R. Pipkorn (German 
Cancer Research Center, Heidelberg). Recombinant baculoviruses 
containing sequences coding for the different PKC isoenzymes were 
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generously donated by Dr. S. Stabel (Max-Delbrueck-Laboratorium, 
Cologne, Germany). Other materials were bought from companies as 
indicated in parentheses: taurosporine (Boehringer, Mannheim), 
K252a (Fluka Chemic A.G., Neu-Ulm), bisindolylmaleimides I and 
III (LC Laboratories, Gruenberg), quercetin, phloretin, PdBu and 
phosphatidylserine (Sigma, Munich), [y-a2P]ATP, spec. act. 5000 Ci/ 
mmol (Hartmann Analytics, Braunschweig). 
2.2. Recombinant PKC isoenzymes 
Sf158 cells were infected with a recombinant PKCIa baculovirus as 
described [11]. Cells were lysed with buffer A (20 mM Tris-HCl, pH 
7.5, 5 mM EDTA, 5 mM EGTA, 10 mM ~-mercaptoethanol, 1 mM 
phenylmethylsulfonyl fluoride, 3 mg/ml leupeptin). The lysate was 
kept on ice for 10 min and then centrifuged at 100000×g for 30 
min. The supernatant (cell extract) was adjusted to 7.5% glycerol 
and used as a source for PKCI.t. Sf9 cells were infected with recombi- 
nant baculoviruses a  a source for other PKC isoenzymes, and cell 
extracts were prepared and used as described previously [12]. 
2.3. Protein kinase assay 
Phosphorylation reactions were carried out in a total volume of 100 
l.tl, containing buffer C (50 mM Tris-HC1, pH 7.5, 10 mM ~-mercap- 
toethanol), 4 mM MgCI2, 10 gg PS, 100 nM TPA, 5 lal of a Sf158 cell 
extract as a source of recombinant PKQt or of Sf9 cell extracts as a 
source of other recombinant PKC isoenzymes, 10 Ixg of syntide 2 as 
substrate, and 35 I.tM ATP containing 1 I.tCi [7-32P]ATP. In some 
experiments PS and TPA were omitted or various inhibitors at con- 
centrations indicated in the text were added. After incubation for 10 
min at 30°C, the reaction was terminated by transferring 50 ~tl of the 
assay mixture onto a 20 mm square piece of phosphocellulose paper 
(Whatman p81), which was washed 3 times in deionized water and 
twice in acetone. The radioactivity on each paper was determined by 
liquid scintillation counting. 
2.4. Autophosphorylation of PKCIx 
Phosphorylation reactions were carried out, using 5 ~tl of the extract 
of baculovirus-infected Sf158 cells expressing PKC~t, essentially as 
described for the protein kinase assay. However, 7 p.Ci of [y-32P]ATP 
was added and the substrate syntide 2 was omitted. The reaction was 
terminated by addition of 250 ~tl of 10% trichloroacetic a id. After 30 
min at 4°C the precipitated proteins were pelleted, redissolved in 
sample buffer, separated by SDS-polyacrylamide g l electrophoresis, 
and visualized by autoradiography of the gels. To analyze in vivo 
PKCI.t autophosphorylation NIH3T3 PKCI.t overexpressing transfec- 
tants were established essentially as previously described [5]. PKQt 
expression was induced by incubating 60% confluent growing trans- 
fectants 3 h in phosphate-free DMEM medium adding 1 ~tM CdC12 
and 300 ~tCi 32p-labelled orthophosphate (Amersham) in a final vo- 
lume of 2 ml. Stimulation of PKCIx kinase activity was performed by 
adding 100 nM phorbol ester for 10 min. Previously inhibitors G6 
6976 and G6 6983 were added for a 20 min period. Cells were scraped 
off, then subjected to immunoprecipitation, SDS-PAGE and autora- 
diography as described [6]. 
Table 1 
Inhibition of PKC~t by various inhibitors 
Inhibitor IC50 (nM) 
K252a 7 
G6 6976 2O 
Staurosporine 40 
Bisindolylmaleimide I 2 000 
Bisindolylmaleimide III 10000 
G6 6983 20000 
Quercetin 4 000 
Phloretin 50 000 
~-Pseudosubstrate > 100 000 
The concentration f the inhibitor at which 50% suppression ofPKCIx 
activity could be observed (ICs0) was determined from data shown in 
Fig. 2 and respective data of quercetin and phloretin (data not 
shown). 
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Fig. 1. Chemical structures of staurosporine, K252a, and stauro- 
sporine-derived compounds. R1 and R2 represent different substitu- 
ents with the exception of staurosporine and K252, where one sub- 
stituent is connected via the bonds R1 and R2 to the N atoms of 
the indole carbazole chromophore. 
3. Results and discussion 
3.1. Inhibition of PKC~t kinase activity by staurosporine and 
staurosporine-related compounds 
Various inhibitors known to suppress PKC activity were 
tested for their capacity to inhibit the phosphorylation of 
syntide 2 by PKC/.t. Most effective in the inhibition of 
PKCkt were staurosporine and the staurosporine-related com- 
pounds K252a and G6 6976 (for chemical structures ee Fig. 
1) with IC50 values in the nM range (40, 7 and 20 nM, re- 
spectively; Fig. 2 and Table 1). K252a, which we had pre- 
viously shown to suppress cPKC (ct,13,y) much more effectively 
than PKC~i [12,13], proved to be a potent inhibitor of PKCkt. 
Whereas staurosporine and K252a are known to suppress 
many protein kinases [14,15], the indolocarbazole G6 6976 
is rather specific for PKC [16]. Moreover, G6 6976 is able 
to differentiate between PKC isoenzymes [12,16,17], inhibiting 
cPKC (ct,[~,7) with much greater efficacy (IC50 values in the 
nM range) than nPKC (8,e,rl) and aPKC (~) (IC50 values in 
the I.tM range). It is intriguing that PKC~t is equally well 
inhibited by G6 6976 as cPKC. As PKCp. is Ca2+-independent 
and activated by phorbol ester [6,11], one would tend to as- 
sociate it with the nPKC group of PKC isoenzymes. However, 
the excellent inhibition by G6 6976, which is atypical for an 
nPKC, as well as various structural and functional properties 
(see [5,6,10,11]) suggest hat PKCkt might represent a novel 
type that does not fit into any of the known PKC subgroups. 
Other staurosporine-derived compounds, the bisindolylmalei- 
mides G6 6983, bisindolylmaleimide I (GF-109203X) and bi- 
sindolylmaleimide III (for chemical structures ee Fig. 1) that 
are potent PKC inhibitors and were also shown to have im- 
proved selectivity for PKCs [16,18], proved to be rather weak 
inhibitors of PKCI.t (Fig. 2 and Table 1). Especially G6 6983 
was extremely ineffective in suppressing PKC~t kinase activity 
in vitro with an IC50 of 20 IxM. 
Changes in the activation of PKCkt kinase activity in vitro 
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Fig. 2. Suppression of PKQt kinase activity by various inhibitors. 
10 Ixg of syntide 2 was phosphorylated by recombinant PKQt (5 ~1 
o! cell extract, 40 mU, 14.4 ~tg protein) in the presence of various 
inhibitors at the indicated concentrations. The Kr~ value for ATP 
w~s determined to be 34.5 tiM. Protein kinase assays were per- 
fo~xned as described in Section 2. (v )  K252a, (v )  G6 6976, ((D) 
st;~urosporine, (• )  bisindolylmaleimide II I,( zx ) bisindolylmaleirnide 
I (GF-109203X), (O) G6 6983, (11) pseudosubstrate peptide of 
PKCS. ICs0 values presented in Tables 1 and 2 were estimated by 
e~.  
as well as in vivo are coupled to changes of the autophos- 
pt~orylation state ([11] and F.J. Johannes unpublished). There- 
fore, staurosporine as well as the inhibitors G6 6976 and G6 
6983 were analyzed regarding their inhibition of PKC~t auto- 
pl~osphorylation. Autophosphorylation was performed in the 
presence of PS/TPA, since TPA as well as the structurally 
unrelated PKC activator bryostatin proved to stimulate 
PKCp~ kinase activity significantly (Fig. 3A). Staurosporine 
and G6 6976 proved to be efficient in inhibiting approx. 
50% autophosphorylation (Fig. 3B) at 100 nM final concen- 
tration whereas G6 6983 did not show any significant inhibi- 
ti~,n of PKC~ in vitro autophosphorylation up to 10 BM 
concentration (Fig. 3B). 
rhe differential potency of G6 6983 and G6 6976 was 
further measured by inhibiting in vivo PKCp~ kinase activity. 
PKQt  overexpressing NIH3T3 transfectants were labelled 
wi~h [aZp]orthophosphate nd PKC~t was activated by stimu- 
lating cells with phorbol ester. As shown in Fig. 3C, immu- 
noprecipitated PKCbt displayed enhanced autophosphoryla- 
tien after incubation of transfectants with phorbol ester 
wlich could be approx. 50% suppressed by adding 20 ~tM 
G(i 6976 (Fig. 3C). Incubation of transfectants with 20 btM 
of G6 6983 did not produce any significant reduction of 
Pd Bu-stimulated autophosphorylation of PKCbt immunopre- 
cipitates (Fig. 3C, right lane). Suppression of PKCla auto- 
phosphorylation (approx. 20% reduction) by G6 6983 could 
be detected by incubating the transfectants at 300 p.M con- 
centrations (data not shown). 
By comparing the chemical structures of staurosporine and 
staurosporine-derived compounds (Fig. 1) with their inhibi- 
tory activity towards PKCbt (Fig. 2 and Table 1), an interest- 
ing structure-activity relationship becomes evident. Com- 
pounds with the intact aromatic ring structure of 
staurosporine (staurosporine, K252a and G6 6976) are effec- 
tive in inhibiting PKQt,  whereas the bisindolylmaleimides 
with the opened central aromatic ring (G6 6983 and bisindol- 
ylmaleimide I and III) are very poor suppressors of PKCB 
activity. This information might be valuable for future at- 
tempts to develop inhibitors of improved selectivity. 
3.2. Inhibition of PKC! l by staurosporine-unrelated compounds, 
pseudosubstrate p ptide of PKC8 and putative 
pseudosubstrate p ptides of PKCti 
Quercetin and phloretin are rather weak and unspecific in- 
hibitors of PKC with IC~0 values of 10 and 20 ~tM, respec- 
tively [19,20]. Similarly high IC,~0 values were found for PKC~t 
(4 and 50 ~tM, respectively; see Table 1). PKQa was not sig- 
nificantly suppressed by the pseudosubstrate peptide of PKC8 
(IC~0 > 100 ~tM; see Fig. 2 and Table 1). Other PKC isoen- 
zymes, such as PKCcx, [3, y and PKCS, are effectively inhibited 
by several of the PKC pseudosubstrate p ptides (Gschwendt 
et al., unpublished ata). This result is in accordance with the 
lack of a classical pseudosubstrate sequence in PKC~t. How- 
ever, as PKCB is activated by TPA in a similar manner to 
other PKC isoenzymes, a site with a pseudosubstrate function 
could be postulated. This prompted us to look for a putative 
pseudosubstrate motif of PKCB. In this context, we tested 
three synthetic PKC B peptides as potential inhibitors of 
PKC B. Peptide 1 (4°'SPLMRVVQSVKHTKRK 419) was cho- 
sen, since it displays some homology to syntide 2, a known 
in vitro substrate of PKCIa [11]. The peptides 2 
(75AHVREMACSIVDQK88) and 3 (>~2FQIRPHALFVHSY- 
RAPAF159), like the known PKC pseudosubstrate sequences, 
are located N-terminal of the two cysteine-rich regions and 
contain the consensus equence RXXA that appears to be an 
essential part of the pseudosubstrate motifs of the other PKC 
isoenzymes. Up to a concentration of 100 ~tM, all three pep- 
tides were unable to inhibit PKCB activity (data not shown). 
These results indicate that the pseudosubstrate r gion of 
PKC~t, if there is any, might differ essentially from those of 
the other PKC isoenzymes and support he above-mentioned 
assumption that PKC B might represent a novel PKC type. 
3.3. Differential inhibition of PKCla and other PKC isoenzymes 
by G6 6983 
Because of the extremely poor suppression of PKQt  activ- 
ity by the PKC inhibitor G6 6983, this compound was chosen 
for further studies. In order to be able to compare the inhibi- 
tion of PKC~t by G6 6983 with that of other PKC isoenzymes, 
we used the same substrate for all assays of PKC activity. As 
Table 2 
Inhibition of PKC isoenzymes by G6 6983 with syntide 2 as sub- 
strate 
PKC IC5o (nM) 
PKCc¢ 7 
PKC~ 7 
PKCy 6 
PKC8 10 
PKC~ 60 
PKC~t 20 000 
PKC kinase activity towards the substrate syntide 2 was measured in 
the presence of various concentrations of G6 6983 as described in 
Section 2. IC~0 values were determined from these data as indicated 
in Table 1. 
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Fig. 3. Autophosphorylation of PKC/.t and its suppression by staur- 
osporine, G6 6983 and G6 6976. (A) Recombinant PKCI, t was au- 
tophosphorylated in the absence of cofactors or in the presence of 
PS (10 I.tg), PS/TPA (100 nM) or PS/bryostatin (BR, 100 nM) as de- 
scribed in Section 2. (B) Autophosphorylation of PKCI.t in the pres- 
ence of PS/TPA was performed as in A without (control, C) and 
with addition of staurosporine, G6 6983, or G6 6976 at the indi- 
cated concentrations. (C) In vivo inactivation of PKC/.t kinase activ- 
ity. PKC~t was immunoprecipitated from a2p-labelled NIH3T3 
PKCla transfectants after stimulation with phorbol ester in the pres- 
ence of 20 ~tM of the respective inhibitor. Equal loads of PKCIx in 
each lane were verified by Western blot analysis (data not shown). 
All autoradiographs shown were exposed overnight. 
syntide 2 is one of the few known specific in vitro substrates 
for PKCIx [11], it was necessary to test its suitability as a 
substrate for other PKC isoenzymes. Syntide 2 is effectively 
phosphorylated by PKC isoenzymes of the cPKC group 
(¢x = 50%, [3 = 43%, y= 33%), the nPKC group (8 = 52%), and 
the aPKC group (4 = 30% relative to the 8-pseudosubstrate 
peptide). Pseudosubstrate-related peptides belong to the 
most effectively phosphorylated substrate peptides that have 
been used for PKC isoenzymes so far. Thus, the inhibition of 
PKCp. and other PKC isoenzymes by G6 6983 could be com- 
pared using syntide 2 as substrate. Again, representatives of 
each PKC subgroup were tested. Whereas PKCI.t was resistant 
to G6 6983 in the gM range (ICs0:20 p.M, see also Table 1), 
the other PKC isoenzymes could be suppressed by G6 6983 
with IC50 values from 7 to 60 nM (Table 2). Again, this in- 
dicates that PKC~t differs essentially from all the other PKC 
isoenzymes known as yet. Based on these results and the dif- 
ferential inhibition of PKC~t autophosphorylation by G6 6983 
compared to G6 6976 (Fig. 3C), G6 6983 promises to become 
a valuable tool for selectively analysing in vivo PKCI.t kinase 
activity in the presence of other PKC isoenzymes. 
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